<DOC>
	<DOCNO>NCT00844597</DOCNO>
	<brief_summary>The specific aim Phase I/II study ass safety intravenous administer Morpholino oligomer direct exon 51 ( AVI-4658 PMO ) .</brief_summary>
	<brief_title>Dose-Ranging Study AVI-4658 Induce Dystrophin Expression Selected Duchenne Muscular Dystrophy ( DMD ) Patients</brief_title>
	<detailed_description>Primary outcome safety , tolerability dose selection future study .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>1 . Has provide write informed assent ( require EC ) parents/guardians provide write informed consent . 2 . Has outofframe deletion ( ) could correct skip exon 51 base DNA sequence data candidate . 3 . Is male age ≥ 5 year ≤ 15 year . 4 . Has muscle biopsy analysis show &lt; 5 % revertant fibres present baseline . 5 . DNA sequence candidate 's dystrophin exon 51 confirms DNA polymorphisms present could compromise PMO duplex formation confirmation vitro dystrophin production AVI4658 exposure fibroblast myoblast vitro culture . 6 . Intact right left bicep muscle alternative arm muscle group . 7 . Is able walk independently least 25 meter . 8 . Has force vital capacity ( FVC ) ≥ 50 % predict require ventilatory support supplemental oxygen . 9 . Receives standard care DMD recommend DMD care recommendation North Star UK TREATNMD . 10 . The parent ( ) legal guardian Subject undergone counsel expectation protocol agree participate . 11 . The parent ( ) legal guardian Subject intend comply study evaluation return study activity . 1 . A DNA polymorphism within exon 51 may compromise PMO duplex formation . 2 . Known antibody dystrophin . 3 . Lacks intact right leave bicep muscle alternative arm muscle group . 4 . A calculated creatinine clearance le 70 % predict normal age base Cockcroft Gault Formula . 5 . A left ventricular ejection fraction ( EF ) &lt; 35 % and/or fractional shortening &lt; 25 % base echocardiography ( ECHO ) screening . 6 . A history respiratory insufficiency define need intermittent continuous supplemental oxygen . 7 . A severe cognitive dysfunction render potential subject unable understand comply study protocol . 8 . Any know immune deficiency autoimmune disease . 9 . A known bleeding disorder receive chronic anticoagulant treatment within three month study entry . 10 . Receipt pharmacologic treatment , apart corticosteroid , might affect muscle strength function within 8 week study entry ( viz. , growth hormone , anabolic steroid ) . 11 . Surgery within 3 month study entry plan anytime duration study . 12 . Another clinically significant illness time study entry . 13 . Subject parent active psychiatric disorder , adverse psychosocial circumstance , recent significant emotional loss , and/or history depressive anxiety disorder might interfere protocol compliance . 14 . Use experimental treatment , participate DMD interventional clinical trial within 4 week study entry participate AVI465833 intramuscular ( i.m . ) trial .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>